PD1 pathway in immune-mediated myopathies
Pathogenesis of dysfunctional T cells revisited
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 7, 2018
- Accepted in final form January 23, 2019
- First Published April 10, 2019.
Author Disclosures
- Samuel Knauss, MD,
- Corinna Preusse, PhD,
- Yves Allenbach, MD, PhD,
- Sarah Leonard-Louis, MD,
- Mehdi Touat, MD,
- Norina Fischer,
- Helena Radbruch, MD,
- Ronja Mothes,
- Vitali Matyash, PhD,
- Wolfgang Böhmerle, MD,
- Matthias Endres, MD,
- Hans-Hilmar Goebel, MD,
- Olivier Benveniste, MD, PhD and
- Werner Stenzel, MD
- Samuel Knauss, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Corinna Preusse, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yves Allenbach, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sarah Leonard-Louis, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mehdi Touat, MD,
Agios Pharmaceuticals, Taiho Oncology, outside the submitted work.
NONE
Funding for travel from Agios Pharmaceuticals and Merck Sharp and Dohme, outside the submitted work.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research grants from Fondation pour la Recherche Medicale (FDM 41635).
NONE
NONE
NONE
NONE
NONE
NONE
- Norina Fischer,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Helena Radbruch, MD,
NONE
NONE
(1) Novartis, (2) Sanofi
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Novartis, (2) Sanofi
(1)Deutsche Forschungsgemeinschaft CRC 130 TP17
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ronja Mothes,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vitali Matyash, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Wolfgang Böhmerle, MD,
NONE
NONE
NOGGO e.V. speaker honoraria, BMS speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NeuroCure Innovation and Flex-Fund, DZNE I2A project, BIH QUEST Replication challenge, BIH QUEST Validation fund
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Matthias Endres, MD,
(1) non profit entity: safety monitoring board of STEMO study at the Center of Stroke research Berlin, no compensation (2) commercial entity: scientific advisory board Boehringer Ingelheim, honoraria paid to institution (3) commercial entity: scientific advisory board Bayer, honoraria paid to institution; (4) commercial entity: scientific advisory board Amgen, honoraria paid to institution; (5) commercial entity: scientific advisory board Covidien; honoraria paid to institution
NONE
(1) Boehringer Ingelheim, speaker honoraria paid to institution (2) Pfizer, speaker honoraria paid to institution(3) Sanofi, speaker honoraria paid to institution (4) Bayer, speaker honoraria paid to institution,(5) BMS, speaker honoraria paid to institution (6) Ever, speaker honoraria paid to institution (7) GSK, speaker honoraria paid to institution (8) Amgen, speaker honoraria paid to institution; (9) Novartis, speaker honoraria paid to institution
(1) Stroke, Editorial Board , no compensation, (2) Journal of Molecular Medicine, Editorial Board, no compensation (3) Neuropsychopharmacology, Editorial Board, compensation; (4) Aktuelle Neurologie, Editorial Board, compensation (modest); (5) Journal of the European Stroke Organization, Editorial board, no compenstaion
NONE
NONE
non profit entity: German Center for Neurodegenerative Diseases (DZNE), employment, compensation (modest)
NONE
NONE
NONE
NONE
(1) Commercial entity Roche, unrestricted grant support to Dept Neurolgy Charite (2) Commercial entity Bayer, unrestricted grant support to the Dept Neurology and Center for Stroke Research Charite for Mondafis Trial (investigator initiated trial) and Berlin AF Registry (investigator initiated trial)
(1) German Ministry of Education and Science (BMBF) grant support (Center for Stroke Research Berlin, (2) Deutsche Forschungsgemeinschaft, grant support (ExcellenceCluster NeuroCure. SFB TR-43; KFO 247,KFO 213) (3) European Union (EUstroke, ARISE, Wake-Up) (4) German Center for Cardiovascular Research (DZHK) (5) Berlin site, German Center for Neurodegenerative Diseases (DZNE), Berlin site (6) Berlin Institute of Health (BiH)
German Center for Cardiovascular Research (DZHK), Berlin site, German Center for Neurodegenerative Diseases (DZNE), Berlin site,(6) Berlin Institute of Health (BiH)
(1) VolkswagenFoundation (Lichtenberg Professorship), (2) CoronaFoundation, (3) Fondation Leducq Transatlantic Network
NONE
NONE
NONE
NONE
NONE
NONE
- Hans-Hilmar Goebel, MD,
NONE
NONE
NONE
editorial advisory board : Neuromuscular Disorders; Neuropathology and Applied Neurobiology, Brain Pathology, Clinical Neuropathology no compensation received from any journal
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Olivier Benveniste, MD, PhD and
Csl Behring Novartis LFB
NONE
(1) CSL Behring: funding for travel at the ACR 2014 conference (2) LFB: funding for travel at the ICNMD 2014 conference, ACR 2017
NONE
NONE
NONE
NONE
(1) Novartis (2) CSL Behring (3) Neovacs
NONE
NONE
NONE
(1) LFB,(2) Novartis, (3) Shire, (4) CSL Behring, (5) Neovacs
(1) DGOS/INSERM, (2) PHRC
NONE
(1) AFM, (2) The Myositis Association
NONE
NONE
NONE
NONE
NONE
NONE
- Werner Stenzel, MD
NONE
NONE
NONE
1 Neuromuscular Disorders editorial board, 5 years 2 Neuropathology and Applied Neurobiology, editorial board, 4 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (S.K., W.B., M.E.) and Department of Neuropathology (C.P., N.F., H.R., R.M., V.M., H.-H.G., W.S.), Charité—Universitätsmedizin, Berlin, Germany; Department of Internal Medicine and Clinical Immunology (Y.A., O.B.), Assistance Public-Hôpitaux de Paris, Sorbonne-Université, INSERM, UMR974, Pitié-Salpêtrière University Hospital; Unité de Pathologie Neuromusculaire (S.L.-L.), Centre de Référence Paris-Est, Groupe Hospitalier Pitié-Salpêtrière; Service de Neurologie 2-Mazarin (M.T.), Hôpitaux Universitaires La Pitié Salpêtrière—Charles Foix, APHP; OncoNeuroTox Group (M.T.), Center for Patients with Neurological Complications of Oncologic Treatments, Hôpitaux Universitaires Pitié-Salpetrière-Charles Foix et Hôpital Percy; Inserm U 1127 (M.T.), CNRS UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM, Université Pierre-et-Marie-Curie, Sorbonne Université, Paris, France; Leibniz ScienceCampus Chronic Inflammation (H.R., R.M., W.S.); Center for Stroke Research Berlin (M.E.), Charité—Universitätsmedizin, Berlin; German Centre for Cardiovascular Research (DZHK) (M.E.); and German Center for Neurodegenerative Diseases (DZNE) (M.E.).
- Correspondence
Dr. Stenzel werner.stenzel{at}charite.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
What's Happening
What's happening in Neurology® Neuroimmunology & Neuroinflammationet al.Neurology, October 28, 2019 -
Article
Inflammatory myopathy with myasthenia gravisThymoma association and polymyositis pathologyNaohiro Uchio, Kenichiro Taira, Chiseko Ikenaga et al.Neurology: Neuroimmunology & Neuroinflammation, December 24, 2018 -
Article
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancerMehdi Touat, Thierry Maisonobe, Samuel Knauss et al.Neurology, August 08, 2018 -
Article
Necrosis in anti-SRP+ and anti-HMGCR+myopathiesRole of autoantibodies and complementYves Allenbach, Louiza Arouche-Delaperche, Corinna Preusse et al.Neurology, January 12, 2018